Acadia Pharmaceuticals to Present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022

Rhea-AI Summary

Acadia Pharmaceuticals, listed on NASDAQ as ACAD, will present at the 1st Annual Needham Virtual Neuroscience Forum on March 16, 2022, at 3:20 p.m. ET. A live webcast of the presentation can be accessed through the company’s website, with an archived version available until April 16, 2022.

Acadia is focused on neuroscience advancements, being known for its therapy for hallucinations in Parkinson’s disease psychosis. The company is also developing treatments for dementia-related psychosis and other neuropsychiatric conditions.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 1^st Annual Needham Virtual Neuroscience Forum on Wednesday, March 16, 2022 at 3:20 p.m. Eastern Time.

A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through April 16, 2022.

About Acadia Pharmaceuticals

Acadia is advancing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on treating psychosis in patients with dementia, the negative symptoms of schizophrenia and Rett syndrome. Our early-stage development efforts are focused on novel approaches to pain management, cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220310005798/en/

Media Contact:

Acadia Pharmaceuticals Inc.

Deb Kazenelson

(818) 395-3043

media@acadia-pharm.com

Investor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

 

Source: Acadia Pharmaceuticals Inc.

FAQ

When will Acadia Pharmaceuticals present at the Needham Virtual Neuroscience Forum?

Acadia Pharmaceuticals will present at the Needham Virtual Neuroscience Forum on March 16, 2022, at 3:20 p.m. ET.

How can I access the Acadia Pharmaceuticals presentation?

You can access the live webcast of Acadia Pharmaceuticals' presentation on their website under the investors section.

What is Acadia Pharmaceuticals known for?

Acadia Pharmaceuticals is known for developing the first approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis.

What are Acadia Pharmaceuticals' development focuses?

Acadia Pharmaceuticals focuses on treating psychosis in dementia patients, schizophrenia, Rett syndrome, and pain management in central nervous system disorders.

Until when will the archived recording of Acadia's presentation be available?

The archived recording of Acadia Pharmaceuticals' presentation will be available until April 16, 2022.